Since its founding in 2008, the team at Seventh Sense has been driven by its mission to improve the quality, convenience and cost-effectiveness of medical care through painless, simplified and safe blood collection. The company is well positioned for the future of the $50 billion in vitro diagnostic industry, which is rapidly evolving due to increased demand for efficiency, the decentralization of testing and treatment and the increasing engagement of patients and consumers in their own care.
The company's proprietary "Touch Activated Phlebotomy™" (TAP) technology platform is being developed by the experienced Seventh Sense scientific team to eliminate the discomfort, inconvenience and expert intervention associated with traditional blood sampling. Drawn through a painless, one-step process by almost anyone, anywhere, anytime, blood samples collected with TAP can be utilized across a broad spectrum of diagnostic applications. TAP's universal, scalable design holds the potential to not only expand the reach and effectiveness of blood collection to hard-to-sample populations and difficult settings, but also to improve the safety and ease of collection for all patients, thereby enhancing care and enabling better diagnostics.